StreetAlpha.app
Home › Stocks › XGN

Exagen Inc. (XGN)

$3.76
▼ −0.27%
LAST CLOSE · NOV 17

Exagen makes AVISE brand blood tests that help doctors diagnose autoimmune and related rheumatic diseases. It last closed at $3.76 on Nov 17, down 0.27% on the day. The average 12-month price target from 3 analysts is $9.67 (+157.1% from the last close), with a high of $11.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is XGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$72.3M
+13.7% vs a year ago
Net income
−$18.2M
−25.1% margin
EPS (diluted)
−$0.76
Free cash flow
−$13.0M
−18.0% margin
Valuation
Market cap
$95.9M
25.5M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$28.1M
At Sep 30
Debt
$22.8M
At Sep 30
Shareholder equity
$13.8M
Shares outstanding
25.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $48.3M$48.3MFY2021FY2022: $45.6M$45.6MFY2022FY2023: $52.5M$52.5MFY2023FY2024: $55.6M$55.6MFY2024FY2025: $66.6M$66.6MFY2025

From XGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on XGN in the past 90 days
Average 12-month target
$9.67
▲ 157.1% upside

Based on 3 analysts who set a price target on XGN in the past 90 days. The average target is $9.67, with a high of $11.00 and a low of $9.00, compared with the last close of $3.76.

Low $9.00Avg $9.67High $11.00
Blue marker: last close $3.76
Highest target$11.00
Average target$9.67
Lowest target$9.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 11Buy$11 → $9
BTIGReiterated
Nov 11Buy$9
Canaccord GenuityMaintained
Oct 19Buy$11
TD CowenMaintained
Oct 13Buy$11
B. Riley SecuritiesReiterated
Aug 5Buy$12
DateFirmActionRatingPrice target
Nov 11Canaccord GenuityTarget loweredBuy$11 → $9
Nov 11BTIGReiteratedBuy$9
Oct 19Canaccord GenuityMaintainedBuy$11
Oct 13TD CowenMaintainedBuy$11
Aug 5B. Riley SecuritiesReiteratedBuy$12
Loading…

Technical Analysis

XGN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 80% below its 20 day and 101% below its 50 day average. It is 36% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot S1 at $3.63, and the nearest resistance the Pivot at $3.77.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 19.4%/day
Key levels
$9.2252 week high+145.2%
$7.5650 day average+101.1%
$6.7820 day average+80.3%
$6.70100 day average+78.2%
$5.12200 day average+36.2%
$4.85Swing high (Jun 15)+29.0%
$3.90Pivot R1+3.7%
$3.77Pivot+0.3%
$3.76Last close
$3.63Pivot S1−3.5%
$2.5952 week low−31.1%
Indicators
RSI (14)27.26Oversold below 30Oversold
MACD-1.03Below its signal lineBearish
Stochastic2.8Near the bottom of its rangeOversold
ADX (14)34.7Trending down
Williams %R-97.7Oversold below −80, overbought above −20Oversold
CCI (20)-140.2Oversold below −100, overbought above 100Oversold
Rate of change−54.9%Change over 10 sessionsBearish
ATR (14)$0.73Typical daily range, 19.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XGN

What happened before

See how XGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in XGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

XGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲53 buying vs 21 selling
  • ▲Held by funds +8.5 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7857+36.8%
In funds' top 10220.0%
Held by funds40.9%32.4%+8.5 pts
New / increased26 / 278 / 15+130.4%
Reduced / sold out16 / 524 / 12−41.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XGN is in one of them and how their past XGN trades turned out.

XGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XGN in an article yet. Here's the latest on the wider market.

About Exagen

Exagen is a medical technology company based in Vista, California, that makes diagnostic tests for autoimmune and related rheumatic diseases. Its main product line, sold under the AVISE brand, includes AVISE CTD, which helps clinicians tell apart conditions with overlapping symptoms, such as lupus and rheumatoid arthritis. Its tests are used mainly by rheumatologists, with primary care physicians, other specialists, hospitals and healthcare systems also among its customers. The company runs its own clinical laboratory to process the tests.

Headquarters
Vista, CA
Founded
2002